Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of targeted therapy and immunotherapy for treatment of small cell lung cancer.

Japanese journal of clinical oncology - 1 Jul 2018

Saito Motonobu, Shiraishi Kouya, Goto Akiteru, Suzuki Hiroyuki, Kohno Takashi, Kono Koji

Abstract excerpt

Targeted therapy against druggable genetic aberrations has shown a significantly positive response rate and longer survival in various cancers, including lung cancer. In lung adenocarcinoma (LADC), specific thyroxin kinase inhibitors against EGFR mutations and ALK fusions are used as a standard treatment regimen and show significant positive efficacy. On the other hand, targeted therapy against driver gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ALK gene
Share to EGFR gene
Share to Immunotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Cancer Research Studies

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Mutation

Share to Small Cell Lung Carcinoma

Source

Identifiers

PMID: 29762727
DOI: 10.1093/jjco/hyy068

Genes

ALK
DLL3
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of targeted therapy and immunotherapy for treatment of small cell lung cancer.PMID 29762727Read ↗

Targeted therapies for small cell lung cancer: Where do we stand?Semantic proximity Read ↗

Targeted therapy for non-small-cell lung cancer: past, present and future.Semantic proximity Read ↗

New and emerging targeted treatments in advanced non-small-cell lung cancer.Semantic proximity Read ↗

Molecular Subtypes and Targeted Therapeutic Strategies in Small Cell Lung Cancer: Advances, Challenges, and Future PerspectivesSemantic proximity Read ↗

Small cell lung cancer: Novel treatments beyond immunotherapySemantic proximity Read ↗

Targeted Therapy and Immunotherapy for Lung Cancer.Semantic proximity Read ↗

Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1Semantic proximity Read ↗

SCLC-State of the Art and What Does the Future Have in Store?Semantic proximity Read ↗

Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy.Semantic proximity Read ↗

Signal pathways and precision therapy of small-cell lung cancerSemantic proximity Read ↗

Targeted and cytotoxic inhibitors used in the treatment of lung cancersSemantic proximity Read ↗

Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.